Executive Summary
The India Healthcare Policy stream captured a single filing on November 14, 2026: Asarfi Hospital Limited's Q2/H1 FY27 audited results, published via newspaper release in The Times of India and Dainik Jagran.
The filing is squarely in scope as a hospital-sector disclosure and provides a clean read on small-cap private hospital economics: consolidated revenue rose 18% YoY to ₹5,303.81 Lakh, EBITDA jumped 34%, PAT surged 43% to ₹609.26 Lakh, and EBITDA margin expanded 260 bps to 22.5% from 19.9%. However, the sequential picture is essentially flat — consolidated revenue of ₹5,303.81 Lakh versus the prior-period standalone figure of ₹5,286.83 Lakh — indicating growth is annual, not sequential, and that Q2 FY27 did not build on Q1. Other income slipped YoY to ₹68.20 Lakh from ₹75.92 Lakh consolidated, a minor but notable drag on total income quality. EPS rose to ₹3.12 standalone (from ₹2.19) and ₹3.10 consolidated (from ₹2.13), confirming operating leverage is flowing to shareholders. The filing carries no insider activity, capital allocation, forward guidance, or transaction data, so the actionable read is a single-company margin-expansion signal rather than a sector-wide policy catalyst; policy-driven hospital names should be monitored for follow-through in subsequent filings.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior India Healthcare Pharma Policy Regulatory Filings digest from November 04, 2026.
Investment Signals (10)
- Asarfi Hospital ↓ (BULLISH)▲
Consolidated revenue from operations grew 18% YoY to ₹5,303.81 Lakh (standalone ₹5,286.83 Lakh vs ₹4,484.67 Lakh), materially above the ~10-12% typical growth for small-cap private hospitals
- Asarfi Hospital ↓ (BULLISH)▲
EBITDA rose 34% YoY, roughly 1.9x the 18% revenue growth rate, demonstrating strong operating leverage in the hospital model
- Asarfi Hospital ↓ (BULLISH)▲
EBITDA margin expanded 260 bps to 22.5% from 19.9%, a meaningful profitability inflection for a small-cap hospital operator
- Asarfi Hospital ↓ (BULLISH)▲
PAT grew 43% YoY to ₹609.26 Lakh consolidated (standalone ₹614.01 Lakh vs ₹430.41 Lakh), the fastest line-item growth in the release and a sign of below-the-line efficiency
- Asarfi Hospital ↓ (BULLISH)▲
Consolidated PBT rose to ₹823.95 Lakh from ₹565.17 Lakh YoY (+45.8%), with standalone PBT at ₹828.71 Lakh vs ₹575.85 Lakh, confirming pre-tax earnings quality
- Asarfi Hospital ↓ (BULLISH)▲
EPS (FV ₹10) rose to ₹3.12 standalone from ₹2.19 and ₹3.10 consolidated from ₹2.13, a 42% YoY increase that supports re-rating if sustained
- Asarfi Hospital ↓ (BULLISH)▲
Consolidated total income reached ₹5,372.01 Lakh vs ₹4,564.98 Lakh YoY, with standalone total income at ₹5,357.72 Lakh vs ₹4,564.41 Lakh, confirming top-line breadth
- Asarfi Hospital ↓ (BULLISH)▲
Audited (not unaudited) H1 FY27 results published in two national/regional dailies signal disclosure discipline and transparency for a small-cap hospital
- Asarfi Hospital ↓ (BEARISH)▲
Sequential revenue was essentially flat (₹5,303.81 Lakh consolidated vs ₹5,286.83 Lakh prior-period standalone), capping the momentum case despite strong YoY optics
- Asarfi Hospital ↓ (BEARISH)▲
Other income declined YoY to ₹68.20 Lakh from ₹75.92 Lakh consolidated, a -10.2% drop that marginally weakens total-income quality
Risk Flags (7)
- Asarfi Hospital / Growth Durability↓ [MEDIUM RISK]▼
Sequential revenue was flat (₹5,303.81 Lakh consolidated vs ₹5,286.83 Lakh prior-period standalone), raising the risk that the 18% YoY growth is base-effect driven rather than sustained demand
- Asarfi Hospital / Disclosure Granularity↓ [MEDIUM RISK]▼
The filing is a newspaper release with no segment mix, occupancy, ARPOB, payer-mix, or bed-capacity data, limiting visibility into the drivers of the 260 bps margin expansion
- Asarfi Hospital / Other Income↓ [LOW RISK]▼
Other income fell 10.2% YoY to ₹68.20 Lakh from ₹75.92 Lakh consolidated, a small but negative quality-of-earnings signal
- Asarfi Hospital / Small-Cap Liquidity↓ [MEDIUM RISK]▼
As a small-cap hospital with limited float, the stock may not reflect the fundamental improvement efficiently and can exhibit outsized volatility
- Asarfi Hospital / Margin Sustainability↓ [MEDIUM RISK]▼
The 22.5% EBITDA margin (up from 19.9%) is a 260 bps jump in one year; without cost-structure disclosure, there is risk of mean reversion if input costs or payer mix normalize
- Asarfi Hospital / Policy Exposure↓ [MEDIUM RISK]▼
As a private hospital operator, the company is exposed to government healthcare scheme pricing (e.g., Ayushman Bharat empanelment rates) and regulatory changes that are not addressed in this release
- ▼
Consolidated PAT (₹609.26 Lakh) is slightly below standalone PAT (₹614.01 Lakh), implying a small subsidiary drag that warrants monitoring
Opportunities (7)
- Asarfi Hospital / Margin Re-rating↓ (OPPORTUNITY)◆
EBITDA margin expansion of 260 bps to 22.5% with 34% EBITDA growth and 43% PAT growth creates a re-rating case if the company sustains margins above 22% in H2 FY27
- Asarfi Hospital / Earnings Momentum↓ (OPPORTUNITY)◆
EPS of ₹3.12 standalone (+42% YoY) implies annualized EPS of roughly ₹12.5; at small-cap hospital multiples this could screen inexpensive versus larger listed peers
- Asarfi Hospital / Operating Leverage↓ (OPPORTUNITY)◆
Revenue growth of 18% translating to 34% EBITDA growth and 43% PAT growth demonstrates a high-incremental-margin model that benefits disproportionately from volume growth
- Asarfi Hospital / H2 FY27 Seasonality↓ (OPPORTUNITY)◆
With Q2 essentially flat sequentially, any Q3/Q4 pickup in hospital occupancy (typical post-monsoon seasonality) could deliver outsized sequential earnings growth
- Asarfi Hospital / Disclosure Catalyst↓ (OPPORTUNITY)◆
The audited H1 FY27 release in national dailies may improve visibility among institutional and HNI investors, potentially broadening the shareholder base
- Asarfi Hospital / Policy Tailwind↓ (OPPORTUNITY)◆
Continued government focus on healthcare schemes (Ayushman Bharat, hospital empanelment) could expand addressable patient volumes for empanelled private hospitals like Asarfi
- Asarfi Hospital / Valuation Gap↓ (OPPORTUNITY)◆
If the stock trades at a discount to larger hospital chains on EV/EBITDA despite superior YoY margin expansion, a valuation catch-up trade may be available
Sector Themes (5)
- Small-Cap Hospital Margin Expansion◆
Asarfi's 260 bps EBITDA margin expansion to 22.5% (from 19.9%) with 34% EBITDA growth suggests small-cap private hospitals are benefiting from operating leverage and possibly improved payer mix, a theme to validate against peer filings [IMPLICATION: favor hospital names showing margin expansion over pure revenue growth]
- YoY Strength vs Sequential Flatness◆
Asarfi's 18% YoY revenue growth against essentially flat sequential revenue highlights a base-effect-driven earnings season for small-cap hospitals, meaning YoY headlines may overstate current-quarter momentum [IMPLICATION: scrutinize QoQ trends before extrapolating growth]
- Audited Disclosure Discipline◆
Asarfi published audited H1 FY27 results in two newspapers (The Times of India, Dainik Jagran), reflecting a regulatory/disclosure norm that improves transparency for small-cap healthcare names [IMPLICATION: disclosure quality is a differentiator in small-cap hospital investing]
- Policy-Linked Volume Sensitivity◆
With no policy-specific disclosure in this filing, the stream's healthcare-policy theme remains unconfirmed by company data; hospital operators' exposure to Ayushman Bharat and related schemes will need to be tracked through empanelment and pricing updates [IMPLICATION: policy catalysts are pending, not yet reflected]
- Earnings Quality Watch◆
Other income declined 10.2% YoY even as operating profit surged, indicating that Asarfi's earnings growth is operationally driven rather than non-operating — a healthy pattern for the hospital sector [IMPLICATION: prefer operators with operating-led PAT growth]
Watch List (7)
-
Monitor Q3 FY27 results for sequential revenue re-acceleration after the flat Q2 (₹5,303.81 Lakh consolidated vs ₹5,286.83 Lakh prior-period standalone); watch whether EBITDA margin holds above 22% [DATE: Q3 FY27 results, expected Jan-Feb 2027]
-
Watch for any investor presentation or earnings call that discloses occupancy, ARPOB, bed capacity, and payer mix to validate the 260 bps margin expansion [DATE: TBD]
-
Track any Ayushman Bharat empanelment or government scheme pricing updates that could affect realizations [DATE: ongoing]
-
Monitor insider/shareholding pattern filings for management conviction signals, absent from this release [DATE: next shareholding disclosure]
- India Healthcare Policy / Regulatory👁
Watch for SEBI/NSE/BSE or MoHFW notices on hospital pricing, medical device regulation, or healthcare scheme expansion that could re-rate the sector [DATE: ongoing]
- Hospital Sector Peers👁
Compare Asarfi's 22.5% EBITDA margin and 18% YoY growth against larger listed hospital chains in upcoming Q2 FY27 filings to assess relative performance [DATE: Nov-Dec 2026]
-
Monitor the small subsidiary drag (consolidated PAT ₹609.26 Lakh vs standalone ₹614.01 Lakh) for any widening gap in H2 FY27 [DATE: Q3 FY27]
Filing Analyses
(1)
14-11-2026
Asarfi Hospital Limited published its Q2/H1 FY27 (quarter and half year ended September 30, 2026) audited standalone and consolidated financial results via newspaper release in The Times of India and Dainik Jagran on November 14, 2026. Consolidated revenue from operations rose 18% YoY to ₹5,303.81 Lakh (standalone ₹5,286.83 Lakh vs ₹4,484.67 Lakh), with EBITDA up 34% and PAT up 43% to ₹609.26 Lakh consolidated (standalone ₹614.01 Lakh vs ₹430.41 Lakh), and EBITDA margin expanding to 22.5% from 19.9%. However, consolidated revenue was essentially flat sequentially versus the immediately prior quarter (₹5,303.81 Lakh vs ₹5,286.83 Lakh standalone prior-period figure), and other income declined YoY (₹68.20 Lakh vs ₹75.92 Lakh consolidated).
- · Consolidated total income ₹5,372.01 Lakh vs ₹4,564.98 Lakh YoY; standalone total income ₹5,357.72 Lakh vs ₹4,564.41 Lakh
- · Consolidated PBT ₹823.95 Lakh vs ₹565.17 Lakh YoY; standalone PBT ₹828.71 Lakh vs ₹575.85 Lakh
- · EPS (FV ₹10/share) basic and diluted ₹3.12 standalone vs ₹2.19 YoY; consolidated ₹3.10 vs ₹2.13
- · Super-Specialty ARPOB rose to ₹23,716
- · Results reviewed by Audit Committee and approved by Board on November 13, 2026
- · Scrip Code: 543943; CIN: L85110JH2005PLC011673
- · Company described as a Dhanbad-based healthcare provider with a 20-year operating track record
Get daily alerts with 10 investment signals, 7 risk alerts, 7 opportunities and full AI analysis of all 1 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India Healthcare Pharma Policy Regulatory Filings
November 03, 2026
India Healthcare Pharma Policy Regulatory Filings — November 03, 2026
October 30, 2026
India Healthcare Pharma Policy Regulatory Filings — October 30, 2026
October 28, 2026
India Healthcare Pharma Policy Regulatory Filings — October 28, 2026
October 27, 2026
India Healthcare Pharma Policy Regulatory Filings — October 27, 2026
🇮🇳 More from India
View all →November 07, 2026
India Pre-Market Regulatory Roundup — November 07, 2026
India Pre-Market Regulatory Roundup
November 07, 2026
India Quarterly Results BSE NSE Announcements — November 07, 2026
India Quarterly Results BSE NSE Announcements
November 07, 2026
India Merger Acquisition MCA Regulatory Filings — November 07, 2026
India Merger Acquisition MCA Regulatory Filings
November 07, 2026
India MCA Corporate Compliance Enforcement — November 07, 2026
India MCA Corporate Compliance Enforcement